New lupus drug PIT565 enters human safety trials
NCT ID NCT06335979
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 31 times
Summary
This early-stage study tests a new drug, PIT565, in 54 adults with active systemic lupus erythematosus (SLE) who haven't improved with standard treatments. The main goal is to check the drug's safety and how the body processes it. Participants will receive increasing doses of PIT565 and be closely monitored for side effects and immune responses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Novartis Investigative Site
WITHDRAWNSofia, 1612, Bulgaria
-
Novartis Investigative Site
RECRUITINGBeijing, 100191, China
-
Novartis Investigative Site
RECRUITINGBeijing, 100730, China
-
Novartis Investigative Site
RECRUITINGBerlin, 10117, Germany
-
Novartis Investigative Site
RECRUITINGMainz, 55131, Germany
-
Novartis Investigative Site
RECRUITINGBudapest, H-1083, Hungary
-
Novartis Investigative Site
RECRUITINGSzeged, 6725, Hungary
-
Novartis Investigative Site
RECRUITINGLeiden, South Holland, 2333 CL, Netherlands
-
Novartis Investigative Site
RECRUITINGSantiago Compostela, A Coruna, 15706, Spain
-
Novartis Investigative Site
RECRUITINGBarcelona, 08035, Spain
-
Novartis Investigative Site
RECRUITINGMadrid, 28034, Spain
-
Novartis Investigative Site
RECRUITINGBern, 3010, Switzerland
-
Novartis Investigative Site
WITHDRAWNSankt Gallen, 9007, Switzerland
Conditions
Explore the condition pages connected to this study.